Analysis of Telmisartan Administered With Antiretroviral Therapy (ART) in Patients With Acute HIV Infection (SEARCH018)

Adjunctive Therapy With Telmisartan Instituted With ART During Acute HIV Infection to Reduce the Establishment of Central Nervous System Reservoirs of HIV and Lymph Node Fibrosis [Southeast Asia Research Collaboration With Hawaii (SEARCH) 018]

This research project will study whether the drug telmisartan administered in conjunction with antiretroviral therapy (ART) will help reduce nervous system infection with HIV. The investigators are studying the effect of this treatment in people who have contracted HIV infection within the past three weeks, and thus have a form of HIV called acute HIV infection. The investigators will measure biological markers of immune activation in the blood and cerebrospinal fluid to see if telmisartan may reduce the spread of HIV reservoirs in affected patients.

Study Overview

• Status: Completed
• Conditions: HIV Infections; Acute HIV Infection
• Intervention / Treatment: Drug: Telmisartan

Detailed Description

Note regarding the primary purpose of the study: In the Study Design section, this protocol is classified as "Other", since it is specifically designed to examine the effect of telmisartan administered in conjunction with ART on the size of HIV reservoirs in the central nervous system.

• Study Type: Interventional
• Enrollment (Actual): 21
• Phase: Phase 1

Contacts and Locations

Study Locations

• Thailand
  • Bangkok, Thailand, 10330
    • Chulalongkorn University Hospital
  • Bangkok, Thailand, 10330
    • Thai Red Cross Aids Research Centre

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Age ≥ 18 years old
• Have protocol-defined acute HIV-1 infection
• Be part of the SEARCH 010/RV 254 study in Bangkok, Thailand
• Ability and willingness to start ART immediately after diagnosis
• Availability for follow-up for the duration of the planned study
• Systolic blood pressure ≥ 110 mmHg
• Agree to undergo lumbar puncture at weeks 0, 48 and 72
• Ability and willingness to provide informed consent. Subjects must understand the study and sign the consent form. Persons who cannot read will have the consent form read to them by a member of the study staff and may then give informed consent by using making a thumb print.

Exclusion Criteria:

• Pregnancy (current or within the last 6 months) or breastfeeding
• Uncontrolled hypertension
• Use of thiazolidinediones or other angiotensin receptor blockers class [losartan, irbesartan, olmesartan, valsartan, candesartan (washout permitted)]
• Screening laboratory values: absolute neutrophil count < 750 cells/mm3, hemoglobin <10 gm/dL creatinine clearance <30 mL/min (estimated by the Cockcroft-Gault equation using ideal body weight)
• Known renal artery stenosis
• Known cirrhosis or severe liver disease
• Unstable coronary artery disease/angina or decompensated congestive heart failure
• Any history of intolerance to any angiotensin receptor blocker
• Need for ongoing potassium supplementation
• Any contraindication to lumbar puncture such as history of bleeding diathesis or cerebral mass lesion

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
No Intervention: Antiretroviral Therapy (ART) only; Acute HIV-infected subjects (n=7) will be randomly assigned to a group that will receive antiretroviral therapy (the current standard of care for HIV patients) for 72 weeks.
Experimental: ART + Telmisartan; Acute HIV-infected subjects (n=14) will be randomly assigned to a group that will receive treatment with telmisartan in addition to ART. Subjects will receive 40mg telmisartan daily for 4 weeks, followed by 80mg telmisartan daily for 44 weeks, to be taken in conjunction with ART. Subjects unable to tolerate 80mg of telmisartan will be able to de-escalate to 40mg daily. After telmisartan is stopped, subjects will continue to take ART for an additional 24 weeks (total 72 weeks).	Drug: Telmisartan

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in level of neopterin in the cerebrospinal fluid (CSF) of patients placed on antiretroviral therapy (ART) administered in conjunction with telmisartan, versus those placed on ART only	Neopterin is a biological marker of immune activation. Its presence in the CSF provides information on the establishment and persistence of HIV viral reservoirs within the central nervous system of HIV-positive patients.	Change from baseline to 48 weeks following ART initiation

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in levels of mast cell progenitor-1 (MCP-1), IP-10, and HIV RNA in the cerebrospinal fluid (CSF)	Will assess CSF levels of MCP-1, IP-10, and HIV RNA. Absolute levels of these compounds will be compared between subjects on ART + telmisartan versus those on ART only.	Change from baseline to 48 weeks following ART initiation
Change in blood plasma levels of neopterin, interleukin-6, D-dimers, soluble cluster of differentiation 14 (sCD14), and soluble cluster of differentiation 163 (sCD163)	Will assess blood plasma levels of these biomarkers in subjects on ART + telmisartan versus those on ART only.	Change from baseline to 48 weeks following ART initiation
Change in absolute concentrations and ratios with respect to creatine of choline, myoinositol, and n-acetylaspartate (NAA) in specified brain regions	These measurements will be made using magnetic resonance spectroscopy (MRS).	Change from baseline to 48 weeks following ART initiation
Test scores on HIV neuropsychological battery	The assessments to be used in this study have been tested for use with native Thai speakers and will be consistent with other SEARCH study tests. SEARCH employs a HIV neurocognitive battery designed to minimize cultural bias, which has been tested in Bangkok.	Change from baseline to 48 weeks following ART initiation

Collaborators and Investigators

• Sponsor: Yale University
• Collaborators: National Institute of Mental Health (NIMH); National Institute of Neurological Disorders and Stroke (NINDS); University of California, San Francisco; Walter Reed Army Institute of Research (WRAIR); University of Hawaii; South East Asia Research Collaboration with Hawaii
• Investigators: Principal Investigator: Serena Spudich, MD, MA, Yale University; Study Chair: Jintanat Ananworanich, MD, PhD, U.S. Military HIV Research Program, Bethesda, Maryland; Principal Investigator: Nittaya Phanuphak, MD, PhD, Thai Red Cross AIDS Research Centre, Bangkok, Thailand

Publications and helpful links

Helpful Links

• Website: South East Asia Research Collaboration with Hawaii

Study record dates

Study Major Dates

• Study Start (Actual): January 28, 2015
• Primary Completion (Actual): June 13, 2018
• Study Completion (Actual): June 13, 2018

Study Registration Dates

• First Submitted: May 22, 2014
• First Submitted That Met QC Criteria: June 19, 2014
• First Posted (Estimate): June 23, 2014

Study Record Updates

• Last Update Posted (Actual): March 9, 2020
• Last Update Submitted That Met QC Criteria: March 4, 2020
• Last Verified: March 1, 2020

More Information

Terms related to this study

• Keywords: Telmisartan; Antiretroviral therapy; Cerebrospinal fluid; Central nervous system; Acute HIV infection
• Additional Relevant MeSH Terms: Pathologic Processes; RNA Virus Infections; Virus Diseases; Blood-Borne Infections; Sexually Transmitted Diseases, Viral; Sexually Transmitted Diseases; Lentivirus Infections; Retroviridae Infections; Immunologic Deficiency Syndromes; Immune System Diseases; Disease Attributes; Slow Virus Diseases; HIV Infections; Infections; Communicable Diseases; Acquired Immunodeficiency Syndrome; Molecular Mechanisms of Pharmacological Action; Antihypertensive Agents; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Telmisartan
• Other Study ID Numbers: 1401013214; 1R01NS084911-01 (NIH); W81XWH-11-2-0174 (Other Identifier: Henry M. Jackson Foundation Cooperative Agreement); R01MH095613 (U.S. NIH Grant/Contract); R01MH104141 (U.S. NIH Grant/Contract)